Basma Radwan
Stock Analyst at Leerink Partners
(1.01)
# 3,968
Out of 5,119 analysts
3
Total ratings
33.3%
Success rate
-12.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Basma Radwan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LRMR Larimar Therapeutics | Reiterated: Buy | $13 | $2.39 | +443.93% | 1 | Sep 14, 2026 | |
| PTCT PTC Therapeutics | Initiated Coverage: Buy | $98 | $65.44 | +49.76% | 1 | Sep 14, 2026 | |
| RYTM Rhythm Pharmaceuticals | Initiated Coverage: Buy | $133 | $112.28 | +18.45% | 1 | Sep 14, 2026 |
Larimar Therapeutics
Sep 14, 2026
Reiterated: Buy
Price Target: $13
Current: $2.39
Upside: +443.93%
PTC Therapeutics
Sep 14, 2026
Initiated Coverage: Buy
Price Target: $98
Current: $65.44
Upside: +49.76%
Rhythm Pharmaceuticals
Sep 14, 2026
Initiated Coverage: Buy
Price Target: $133
Current: $112.28
Upside: +18.45%